Pevarello P - Search Results

1

Novel P2X7 Antagonist Ameliorates the Early Phase of ALS Disease and Decreases Inflammation and Autophagy in SOD1-G93A Mouse Model.

Apolloni S, Fabbrizio P, Amadio S, Napoli G, Freschi M, Sironi F, Pevarello P, Tarroni P, Liberati C, Bendotti C, Volonté C. Apolloni S, et al. Among authors: pevarello p. Int J Mol Sci. 2021 Sep 30;22(19):10649. doi: 10.3390/ijms221910649. Int J Mol Sci. 2021. PMID: 34638992 Free PMC article.

2

P2X7 antagonists for CNS indications: recent patent disclosures.

Pevarello P, Bovolenta S, Tarroni P, Za L, Severi E, Torino D, Vitalone R. Pevarello P, et al. Pharm Pat Anal. 2017 Mar;6(2):61-76. doi: 10.4155/ppa-2016-0044. Epub 2017 Mar 1. Pharm Pat Anal. 2017. PMID: 28248151 Review.

3

Ca(2+) release-activated Ca(2+) channel inhibitors.

Pevarello P, Cainarca S, Liberati C, Tarroni P, Piscitelli F, Severi E. Pevarello P, et al. Pharm Pat Anal. 2014 Mar;3(2):171-82. doi: 10.4155/ppa.14.7. Pharm Pat Anal. 2014. PMID: 24588594 Review.

4

FFA4/GPR120 agonists: a survey of the recent patent literature.

Formicola R, Pevarello P, Kuhn C, Liberati C, Piscitelli F, Sodano M. Formicola R, et al. Among authors: pevarello p. Pharm Pat Anal. 2015;4(6):443-51. doi: 10.4155/ppa.15.33. Pharm Pat Anal. 2015. PMID: 26580993 Review.

5

Kinase inhibitors for CNS diseases: an analysis of the recent patent literature.

Amigoni F, Legnaghi E, Pevarello P. Amigoni F, et al. Among authors: pevarello p. Pharm Pat Anal. 2012 May;1(2):177-92. doi: 10.4155/ppa.12.19. Pharm Pat Anal. 2012. PMID: 24236782 Review.

6

IP issues facing researchers by Gino D'Oca.

Almarsson O, Angiolini M, Baell J, Giardina G, Ingham A, Hughes A, Pevarello P, Sindelar R. Almarsson O, et al. Among authors: pevarello p. Pharm Pat Anal. 2012 May;1(2):129-35. doi: 10.4155/ppa.12.15. Pharm Pat Anal. 2012. PMID: 24236778

7

Ion channel blockers for the treatment of neuropathic pain.

Colombo E, Francisconi S, Faravelli L, Izzo E, Pevarello P. Colombo E, et al. Among authors: pevarello p. Future Med Chem. 2010 May;2(5):803-42. doi: 10.4155/fmc.10.19. Future Med Chem. 2010. PMID: 21426204 Review.

8

Preclinical evaluation of PNU-151774E as a novel anticonvulsant.

Fariello RG, McArthur RA, Bonsignori A, Cervini MA, Maj R, Marrari P, Pevarello P, Wolf HH, Woodhead JW, White HS, Varasi M, Salvati P, Post C. Fariello RG, et al. Among authors: pevarello p. J Pharmacol Exp Ther. 1998 May;285(2):397-403. J Pharmacol Exp Ther. 1998. PMID: 9580576

9

PNU-151774E protects against kainate-induced status epilepticus and hippocampal lesions in the rat.

Maj R, Fariello RG, Ukmar G, Varasi M, Pevarello P, McArthur RA, Salvati P. Maj R, et al. Among authors: pevarello p. Eur J Pharmacol. 1998 Oct 16;359(1):27-32. doi: 10.1016/s0014-2999(98)00554-8. Eur J Pharmacol. 1998. PMID: 9831289

10

Biochemical and electrophysiological studies on the mechanism of action of PNU-151774E, a novel antiepileptic compound.

Salvati P, Maj R, Caccia C, Cervini MA, Fornaretto MG, Lamberti E, Pevarello P, Skeen GA, White HS, Wolf HH, Faravelli L, Mazzanti M, Mancinelli E, Varasi M, Fariello RG. Salvati P, et al. Among authors: pevarello p. J Pharmacol Exp Ther. 1999 Mar;288(3):1151-9. J Pharmacol Exp Ther. 1999. PMID: 10027853

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

40 results

Search Page